Journal of Immunotherapy

Skip Navigation LinksHome > October 2012 - Volume 35 - Issue 8 > Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lym...
Journal of Immunotherapy:
doi: 10.1097/CJI.0b013e31826e8f5f
Clinical Studies

Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma

Pilon-Thomas, Shari*,†; Kuhn, Lisa*; Ellwanger, Sabine; Janssen, William; Royster, Erica§; Marzban, Suroosh§; Kudchadkar, Ragini§; Zager, Jonathan§; Gibney, Geoffrey§; Sondak, Vernon K.*,§; Weber, Jeffrey*,†,§; Mulé, James J.*,†,§; Sarnaik, Amod A.*,§

Collapse Box


A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Call for Papers

Journal of Immunotherapy has issued a call for papers. With an impact factor of 3.203, JOI is a leading journal in the fields of immunology and oncology.

For manuscript submission, go to:

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.